Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Douglas

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Medicinal Chemistry|October 3, 2012
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitorsTao Liu, Somarajan J Nair, André Lescarbeau, et al.
Blood|December 14, 2017
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphomaSteven M Horwitz, Raphael Koch, Pierluigi Porcu, et al.
Antiviral Research|January 14, 2025
Corrigendum to "Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis B" [Antivi. Res. 231 (2024) 1-13/106017]Yijie Tang, Mingzhu Xu, Cong Wang, et al.
Nature|November 10, 2016
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cellsOlivier De Henau, Matthew Rausch, David Winkler, et al.
Journal of Translational Medicine|January 10, 2024
Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesisXin Tracy Liu, Yu Huang, Da Liu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 11, 2018
Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK WorkshopAnna Zuk, Paul M Palevsky, Linda Fried, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Journal of Hepatology|November 8, 2025
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access programChristiane Stern, Véronique Loustaud-Ratti, Cihan Yurdaydin, et al.
Ebiomedicine|April 1, 2023
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population levelAnouschka Akerman, Vanessa Milogiannakis, Tyra Jean, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Medicinal Chemistry|October 3, 2012
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitorsTao Liu, Somarajan J Nair, André Lescarbeau, et al.
Blood|December 14, 2017
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphomaSteven M Horwitz, Raphael Koch, Pierluigi Porcu, et al.
Antiviral Research|January 14, 2025
Corrigendum to "Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis B" [Antivi. Res. 231 (2024) 1-13/106017]Yijie Tang, Mingzhu Xu, Cong Wang, et al.
Nature|November 10, 2016
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cellsOlivier De Henau, Matthew Rausch, David Winkler, et al.
Journal of Translational Medicine|January 10, 2024
Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesisXin Tracy Liu, Yu Huang, Da Liu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 11, 2018
Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK WorkshopAnna Zuk, Paul M Palevsky, Linda Fried, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Journal of Hepatology|November 8, 2025
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access programChristiane Stern, Véronique Loustaud-Ratti, Cihan Yurdaydin, et al.
Ebiomedicine|April 1, 2023
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population levelAnouschka Akerman, Vanessa Milogiannakis, Tyra Jean, et al.
Pageof 5